Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer
July 9th 2021
The combination of galinpepimut-S and pembrolizumab has demonstrated promising clinical immunobiological activity in patients with Wilms Tumor 1–positive, relapsed or refractory, platinum-resistant advanced metastatic ovarian cancer, according to results from an ad-hoc analysis of a phase 1/2 trial.